Onesource Specialty Pharma Limited — Q1 FY26 earnings call

Call held 5 Aug 2025

Management summary

OneSource Specialty Pharma delivered a strong Q1 FY26, characterized by significant margin expansion and a transition toward commercial-stage revenues. Management identified FY26 as a major inflection point, particularly as the company prepares for the global launch of Semaglutide generics starting in Q4. The strategic focus is currently on accelerating capacity and integrating two high-margin CDMO assets in Poland and Baroda.

Highlights

  • Revenue reported at ₹327.3 crores, representing a 12% YoY growth

  • EBITDA grew 37% YoY to ₹88.5 crores, with margins expanding 500 bps to 27%

  • Adjusted PAT turned positive at ₹37.1 crores compared to a loss in the previous year

  • Organic revenue guidance set at $400 million by FY28, with potential to exceed $500 million including M&A

  • Capacity expansion for drug-device combinations accelerated to 200 million units by end of CY2026

  • Successful completion of 25 inspections during the quarter, including USFDA and ANVISA approvals

  • Credit rating upgraded to the 'A' family, reflecting improved financial management

Concerns

  • Ongoing Judicial Matters with Novo Nordisk

Key financials

  1. Revenue ₹327.3 Cr +12%YoY
  2. EBITDA ₹88.5 Cr +37%YoY
  3. EBITDA Margin 27%
  4. Adjusted PAT ₹37.1 Cr
  5. Adjusted EPS ₹3.2

What they filed

Q1 FY27: revenue up 37.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue334 393 426 327 376 +13%290 −26%428 +0%449 +37%
EBITDA77 142 183 88 106 +38%17 −88%92 −50%123 +40%
Net profit-42 -69 98 0 10 +124%-89 −29%5 −95%25
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Organic Revenue Target Revenue · FY28 · High confidence $400 million
    our path to meet the growth aspirations which we have laid out, which is to be a $400 million revenue company organically by FY '28.

    — Neeraj Sharma, CEO & MD

  • Inorganic Revenue Contribution (Poland & Baroda) Revenue · FY27 · High confidence $100 million
    fully booked and committed to deliver $100 million of revenues at the bare minimum in the next year and that's $36 million to $40 million of EBITDA.

    — Arun Kumar, Founder & Non-Executive Chairperson

Capacity

  • Cartridge and Vial Capacity Capacity · by end of calendar 2026 · High confidence 200 million units
    So we would be having now this capacity, all capacity up and qualified by end of calendar 2026.

    — Neeraj Sharma, CEO & MD

Debt

  • Debt-to-EBITDA Ratio Debt · FY26 · Medium confidence below 1.5x
    our target debt-to-EBITDA to stay below 1.5x during the course of this year as we are accelerating some of our capex investments.

    — Anurag Bhagania, CFO

Margin

  • EBITDA Margin for Acquired Assets Margin · FY27 · High confidence 36% to 40%
    We currently have approximately $65 million of revenues for this year with an EBITDA in the 36% to 40% range

    — Arun Kumar, Founder & Non-Executive Chairperson

Risks & concerns

  • Ongoing Judicial Matters with Novo Nordisk

    high

    The matter involving partner Dr. Reddy's is sub judice; management refused to discuss details.

    Management deflected

  • Temporary Leverage Increase

    medium

    Debt-to-EBITDA may temporarily exceed the 1.5x target due to accelerated capex investments.

    Management acknowledged

  • Seasonality in Base Business

    low

    Antibiotics and cold products in the injectable/soft gelatine segments have inherent seasonal fluctuations.

    Management acknowledged

Areas of evasion (2)

  • Ongoing litigation with Novo Nordisk (sub judice)
  • Specific investment amount in Xbrane

Q&A highlights

2 direct
Semaglutide Generic Launch Timelines and Risks Partial
Now when that approval comes and who comes first, I think it's really very difficult for anyone to answer that.

Investors are focused on the timing of the Semaglutide patent cliff; management admits approval timing is uncertain but remains confident in the complex product barrier.

Asked by Anand Mundra, Soar Wealth

Novo Nordisk Guidance Cuts and Client Reactions Direct
we are a CDMO and we go by what our customers contract with us, right? And at this time, they are increasing forecasts, willing to pay upfronts

Clarifies that despite innovator (Novo) volatility, generic demand and CDMO order books for OneSource are actually expanding.

Asked by Nitin Agarwal, DAM Capital

Delays in Liraglutide and Teriparatide Launches Direct
Liraglutide for Europe, we have already manufactured this quarter... the actual launch will depend upon, again, as I said, customer's options

Explains that launch delays are due to customer priorities, not manufacturing or regulatory hurdles at OneSource.

Asked by Aman Vij, Astute Investment Management

2 min read 5 chapters

Detailed narrative

FY26 as a Strategic Inflection Point

Management emphasized that FY26 represents a critical transition from pre-approval R&D revenues to commercial-scale supplies. While H1 is expected to be muted due to the execution of Master Service Agreements (MSAs), H2 is projected to see a significant pickup driven by commercial supplies of Semaglutide. The company has already secured confirmed purchase orders for these launches, providing high visibility into the second-half performance.

Inorganic Expansion and Global Footprint

The Board has approved the evaluation of acquiring two CDMO assets in Poland and Baroda, which are currently promoter-held. These assets are expected to add at least $100 million in revenue and $36-$40 million in EBITDA by FY27. The Polish facility, which is USFDA approved for both pharma and biologics, provides OneSource with a crucial global footprint and de-risks customer concentration by offering an additional site for GLP-1 expansion.

GLP-1 Market Dynamics and Demand

Despite news of innovators cutting guidance, OneSource reports that its generic customers are revising their forecasts upward. Management noted that current market numbers in regions like Canada and Brazil are constrained by supply rather than demand. With generic entry, they expect a significant volume surge driven by improved access and lower price points, particularly in underserved emerging markets.

Accelerated Capacity Expansion

OneSource is accelerating its Phase 2 capacity expansion for drug-device combinations, aiming to have 200 million units of qualified capacity by the end of calendar year 2026. This is a significant advancement from the previous FY28 timeline. The expansion is supported by 'take-or-pay' contracts, which reinforce management's confidence in the high utilization of these new lines as markets open up.

Operational Excellence and Compliance

The company maintained a perfect compliance record during the quarter, successfully navigating 25 inspections from regulatory agencies and customers. Key approvals were received from the USFDA and ANVISA, which management cited as a core competitive advantage in the complex injectable and biologics space. This track record is essential for securing long-term contracts with 'marquee' global pharmaceutical customers.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls